Adaptive Biotechnologies Q2 2023 Earnings Report

Adaptive Biotechnologies EPS Results

• Actual EPS: -$0.33
• Consensus EPS: -$0.33
• Beat/Miss: Met Expectations
• One Year Ago EPS: -$0.37

Adaptive Biotechnologies Revenue Results

• Actual Revenue: $48.93 million
• Expected Revenue: $44.87 million
• Beat/Miss: Beat by +$4.06 million
• YoY Revenue Growth: +12.10%

Adaptive Biotechnologies Announcement Details

• Quarter: Q2 2023
• Date: 8/2/2023
• Time: After Market Closes

Adaptive Biotechnologies (NASDAQ:ADPT), a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.